Discontinued — last reported Q3 '21
Edwards Lifesciences Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value increased by 97.5% to $16.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 29.2%, from $22.60M to $16.00M. Over 5 years (FY 2020 to FY 2025), Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value shows a downward trend with a -46.6% CAGR.
other_fair_value_measurement_with_unobservable_inputs_re_2a44fd| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $93.00M | $94.10M | $76.00M | $73.10M | $52.20M | $39.70M | $40.20M | $40.90M | $14.00M | $10.30M | $5.00M | $5.00M | $8.80M | $21.50M | $22.60M | $22.60M | $8.10M | $8.10M | $16.00M |
| QoQ Change | — | +1.2% | -19.2% | -3.8% | -28.6% | -23.9% | +1.3% | +1.7% | -65.8% | -26.4% | -51.5% | +0.0% | +76.0% | +144.3% | +5.1% | +0.0% | -64.2% | +0.0% | +97.5% |
| YoY Change | — | — | — | — | -43.9% | -57.8% | -47.1% | -44.0% | -73.2% | -74.4% | -87.8% | -64.3% | — | +108.7% | +352.0% | +352.0% | -8.0% | -62.3% | -29.2% |